Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

(124,717) (108,665)

-------------------------------------------------------------------------

Deficit, end of period $(127,817) $(111,151)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Basic and diluted loss per common share $ (0.03) $ (0.03)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Weighted avg. number of common shares

outstanding (000's) 94,464 74,229

-------------------------------------------------------------------------

-------------------------------------------------------------------------

STATEMENTS OF CASH FLOWS Three months ended

Unaudited - In Thousands of Canadian dollars July 31,

2007 2006

----------------------

Loss for the period $ (3,100) $ (2,486)

Items not affecting cash:

Amortization 137 226

Stock-based compensation 133 147

Accretion of convertible royalty

participation units 421 300

Changes in non-cash working capital items

relating to operating activities (13) (1,295)

-------------------------------------------------------------------------

Cash used in operating activities $ (2,422) $ (3,108)

-------------------------------------------------------------------------

Issuance of common shares, net of issue costs
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Ascendis Pharma ... that applies its innovative TransCon technology to address ... results from a six-month Phase 2 study to ... Growth Hormone in 53 treatment-naïve, pre-pubertal children with ... are extremely pleased with the top-line results from ...
(Date:7/30/2015)... 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... the second $1.0M tranche under a previously awarded ... valued at up to $3.0 million to support ... as a potential medical countermeasure to mitigate acute ... awarded an initial $1.0 million under this grant ...
(Date:7/30/2015)... ... 30, 2015 , ... GEA's Pony™ NS2006L is ... up to 1500 bar. The sanitary design gauge of the NS2006L is well ... The Pony™ NS2006L homogenizer is an ideal solution for the processing of ...
(Date:7/29/2015)... , July 30, 2015 ... santé, publie ses résultats pour le premier semestre ... commente les résultats. Visionner l,interview vidéo ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de l,interview ... - Moteurs de croissance - Diabète ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... (Nasdaq: NXXI ), a developer and marketer ... levels, improve cardiovascular health, enhance memory and address chronic ... it redeemed all of its Series I outstanding Convertible ... shares. The Company redeemed 3,594 shares for a total ...
... 5:00 p.m. EDT - SOUTH SAN FRANCISCO, Calif., ... SNSS ) today reported financial results for the fourth ... for the year ended December 31, 2008 was $5.4 ... of December 31, 2008, cash, cash equivalents and marketable ...
... on probiotic microorganismsActive ingredient easily integrated into consumer products ... Association of Dental Research annual conference in Miami ... Germany and MIAMI, April 1 With an eye ... affecting an estimated 5 billion people world-wide, BASF -- ...
Cached Biology Technology:Nutrition 21 Redeems Series I Convertible Preferred Shares 2Nutrition 21 Redeems Series I Convertible Preferred Shares 3Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 2Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 3Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 4Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 5Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 6Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 7Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 8Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 9Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 10Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 11BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth 2BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth 3BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth 4BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth 5
(Date:7/31/2015)... La 10 th International Conference on Genomics ... 22 al 25 de octubre de 2015 en ... conferencia celebra su décimo aniversario. Desde su inauguración en el ... reuniones anuales más influyentes del mundo en el campo ,ómico, ... y mejores a nivel científico. ICG-10 se ...
(Date:7/31/2015)... -- The 10 th International Conference on Genomics (ICG-10, ... 2015, in Shenzhen , China ... th anniversary this year. Since its inauguration in 2006, ... meetings in the ,omics, fields, and is one of the ... ICG-10 focuses on recent breakthroughs and advances in ,omics, research ...
(Date:7/27/2015)... LOS ANGELES , July 27, 2015 /PRNewswire/ ... providing evidence- and experience-based clinical improvement solutions, today ... coordination solution is now available on Android smartphones ... at inpatient and post-care organizations can use ZynxCarebook ... the same patient,s condition, streamline care transitions to ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... with more corals and fish generate predictably greater levels ... This has important implications for understanding the behaviour of ... monitoring environmental health by listening to reefs. Contrary ... noisy places, with fish and invertebrates producing clicks and ...
... their abilities to counsel patients on a healthy diet and ... to a study by the University of Michigan Cardiovascular Center. ... time, being overweight, and if the doctor had adequate training ... study, published online ahead of print Oct. 1 in ...
... (September 21, 2010) For decades scientists believed ... contact with Homo sapiens , but new ... shows these sturdy ancients could adapt, innovate and ... by anthropologist Julien Riel-Salvatore challenge a half-century of ...
Cached Biology News:Taking the pulse of coral reefs 2Doctor's health habits affect patient counseling 2Neanderthals more advanced than previously thought 2
... The Biomek FX P is ... an,up-to-date hardware design for greater positional accuracy and ... just about any application. It can be configured ... its large deck capacity, the Biomek FX P ...
BD Falcon, microtest ELISA plate 96 well flat-bottom, clear. Polystyrene, nonsterile, no lid (25/sp, 100/ca) Packaging: 25 / pack, 100 / case ...
... GenomeLab GeXP Genetic Analysis System provides high-throughput, ... PCR*. The systems patented priming strategy ... PCR analysis to just a few genes ... more genes per reaction and more samples ...
... electrophoresis hood is a component ... Placed on the transilluminator, it ... and provides a darkroom environment ... lab bench. This 13 x ...
Biology Products: